CTLA4 and melanoma: This is a clinically significant rate considering the substantial proportion of patients displaying poor prognostic factors (eg, 43%, 63%, and 39% had stage M1d disease, >3 metastatic sites, and elevated LDH levels, respectively) and heavily pretreated melanoma (including 45% and 87% patients with ≥3 prior therapy lines and anti-CTLA-4 and anti-PD-1 combination pretreatment, respectively).